The Generics Industry in Japan is analyzed through an industry overview which spans the data from 2012 till 2021. An analysis of the industry's value and volume data is included along with an industry segmentation by geography. Industry forecast of the industry is also included.
The development of the generic drugs sector in Japan has been a long standing plan of the Japanese government. The country has one of the highest healthcare costs amongst the G8 countries and the government has been focusing on developing the generics market in order to combat the rising healthcare and pharmaceutical costs. Due to this, the growth of the Japanese generics market does lag behind its peers countries.
Having experienced fluctuating growth in recent years, the Japanese generics industry has finally stabilized in terms of volume in the last year or so. The market's growth in terms of value is also expected to stabilize in the near future. The Japanese government plans to increase the share of the generics segment to nearly 80% of the total pharmaceutical market volume by the end of 2020.
Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.
Players analyzed include Daiichi Sankyo, Lupin, Sanofi SA, Teva Pharmaceutical Industries, Sawai Pharmaceutical Company and others. This concludes this comprehensive research report.
Key Topics Covered:
A. Executive Summary
B. Analyzing the Global Generics Industry
C. Generics Industry in Asia Pacific
D. Generics Industry in Japan
E. Generics Industry in Japan: Porter's Five Forces Strategy Analysis
F. Pricing & Reimbursement in Japan
G. Major Industry Players
- Allergan Plc
- Daiichi Sankyo Co., Ltd.
- Sanofi SA
- Sawai Pharmaceutical Company Ltd
- Teva Pharmaceutical Industries Limited
For more information about this report visit http://www.researchandmarkets.com/research/v3dmtd/analyzing